Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of selinexor + daratumumab + thalidomide + dexamethasone in first-relapse multiple myeloma
ChiCTR2500095089Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor, daratumumab, thalidomide and dexamethasone in multiple myeloma (MM), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Very good partial response, Complete remission and 2 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
selinexordaratumumabthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500095089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095089.